Hansoh Pharma Presents Positive Interim Overall Survival Results for Risvutatug Rezetecan in Relapsed Small Cell Lung Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-13
Category: health
Source: Hansoh Pharmaceutical Group Co., Ltd. Press Releases

Hansoh Pharmaceutical Group Co., Ltd. presented interim analysis results from the Phase 3 ARTEMIS-008 study of risvutatug rezetecan (HS-20093) in patients with relapsed small cell lung cancer (SCLC) at the 2026 World Conference on Lung Cancer (WCLC). The study demonstrated a statistically significant and clinically meaningful improvement in overall survival.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai